SCHEMBL1883232

SCHEMBL1883232

COc1ccccc1N1CCN(c2ccc(S(=O)(=O)O)cn2)CC1.NC(=O)c1ccc(F)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
RPS6KB1 P23443 1/20 0.48
KMT2A Q03164 3/20 0.48
GFER P55789 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 2/20 0.47
LMNA P02545 4/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.46
GLA P06280 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 2/20 0.44
TP53 P04637 2/20 0.44
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
POLB P06746 1/20 0.42
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883207 0.88 RPS6KB1 (0.49) ALDH1A1RPS6KB1KMT2AMEN1GAA
SCHEMBL1881316 0.86 KDM4E (0.52) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL1879254 0.86 KMT2A (0.45) ALDH1A1RPS6KB1KMT2AMEN1LMNA
SCHEMBL1883230 0.85 ALDH1A1 (0.48) ALDH1A1KMT2AGFERMEN1GAA
SCHEMBL1881342 0.85 RPS6KB1 (0.45) ALDH1A1RPS6KB1GAALMNATSHR
SCHEMBL4368487 0.84 KMT2A (0.46) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL1887570 0.84 RPS6KB1 (0.45) RPS6KB1KMT2AMEN1LMNAGLA
SCHEMBL4371350 0.83 KMT2A (0.47) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL4370142 0.82 KMT2A (0.45) ALDH1A1KMT2AMAPTTP53
SCHEMBL4374084 0.82 CNR2 (0.43) ALDH1A1KMT2AGAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US claimed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US claimed
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS STS, TPMT, DPYD ALDH1A1 392/4885RPS6KB1 536/4885KMT2A 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.